Taste Properties of HIV Inhibitor

Phase 1

Completed

• Conditions: HIV Infections
• Interventions: Drug: BMS-955176

• Registration Number: NCT02608918
• Lead Sponsor: ViiV Healthcare

Brief Summary

The purpose of the study is to assess the taste properties of HIV inhibitor

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-11-17
• Study First Submitted QC: 2015-11-17
• Study First Posted: 2015-11-20
• Study Start: 2016-01-05
• Primary Completion: 2016-05-24
• Study Completion: 2016-05-24
• Status Verified: 2018-04
• Last Update Submitted: 2018-04-13
• Last Update Posted: 2018-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Men and women of non-childbearing potential professional sensory panelists
• Aged between 25 and 80 years

Exclusion Criteria

• History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness
• Positive HIV test

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BMS-955176	BMS-955176	BMS-955176 specified dose on specified days

Primary Outcome Measures

Name	Time	Method
Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria	Up to 2 years

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇸 Woburn, Massachusetts, United States